Submit Manuscript  

Article Details


Histone Deacetylase Inhibitors in Cancer Therapy

Author(s):

Yijie Sun, Fanghui Lu *, Yanyi Sun , Saichao Yue and Yaohe Wang   Pages 1 - 9 ( 9 )

Abstract:


Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments have been discorvered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways. HDACs, therefore, are characterized as promising cancer therapeutic targets, and their inhibitors are under rapid development. Here, we discuss HDAC inhibitors in terms of their functional mechanism establishing the anti-tumor effects and potential clinical applications including the synergistical effects in combinational treatment.

Keywords:

Histone Deacetylase, Inhibitors, Epigenetics, Cancer treatment

Affiliation:

National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Department of Neurosurgical Sciences, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou



Read Full-Text article